Toronto, Ontario — January 13, 2026 — Leads & Copy —
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) announced it has surpassed 50% patient enrollment in MAVERIC, its Phase III trial evaluating CardiolRx™ for preventing disease recurrence in patients with recurrent pericarditis.
The company expects full enrollment in the second quarter of 2026.
More than 15 cardiovascular centers in the U.S. are enrolling patients, with additional sites coming online in Europe and Canada.
Dr. Andrew Hamer, Chief Medical Officer and Head of Research & Development at Cardiol Therapeutics, said that surpassing 50% enrollment in MAVERIC reflects the high unmet medical need in recurrent pericarditis and the confidence investigators have in the trial’s design.
David Elsley, President and Chief Executive Officer, noted the importance of evaluating additional treatment options and cited data from the ARCHER study demonstrating improvements in cardiac structure in patients with myocarditis, reinforcing the position that CardiolRx™ has the potential to change the management of recurrent pericarditis.
The MAVERIC Phase III trial builds on results from Cardiol’s Phase II MAvERIC-Pilot study, in which patients treated with CardiolRx™ experienced reductions in pericarditis pain and inflammation, along with a reduction in recurrence events per year. CardiolRx™ was also shown to be safe and well tolerated in the Phase II trial.
The MAVERIC trial is expected to enroll about 110 patients across 25 cardiovascular research centers in the United States, Canada, and Europe. The primary endpoint is freedom from a new episode of recurrent pericarditis after six months. Secondary endpoints include the percentage of days with no or minimal pericarditis pain, changes in pericarditis pain scores, and changes in the inflammatory biomarker C-reactive protein (CRP).
Cardiol Therapeutics Inc. is focused on advancing anti-inflammatory and anti-fibrotic therapies for heart disease. The company’s lead drug candidate, CardiolRx™, modulates inflammasome pathway activation.
The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.
The ARCHER Program is also studying CardiolRx™ in acute myocarditis.
The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure.
Contact: Investor.relations@cardiolrx.com
Source: Cardiol Therapeutics
